Celcuity Inc

Celcuity Inc. leads the fight against solid tumors with pioneering targeted therapies, showing strong market momentum and investor confidence despite current losses.

Celcuity Inc. reports 2025 losses but strong cash reserves, keeping its high‑impact oncology drug gedatolisib on track toward $2.5 B peak revenue and regulatory milestones.

Celcuity’s Phase 3 VIKTORIA‑1 results show Gedatolisib improves PFS in PIK3CA‑wild‑type breast cancer, expanding its therapeutic reach and boosting investor confidence.

Celcuity Inc.’s (NASDAQ: CELC) stock surged nearly 48% after the company announced positive Phase III results for its investigational PI3K-targeted therapy, gedatolisib, in treating hormone-receptor-positive, HER2-negative breast cancer.

Celcuity Inc., a biotechnology company, reported a quarterly loss of $0.93 per share, exceeding market expectations and causing its stock price to decline.

Celcuity Inc. has made significant financial moves, including a $248.7 million debt and stock offering, to support its clinical trials and development of targeted therapies for breast cancer and other solid tumors.

Celcuity Inc., a clinical-stage biotech company, is poised for a potential breakthrough with the upcoming announcement of its phase 3 VIKTORIA-1 trial results, which could redefine treatment paradigms for advanced breast cancer.

Celcuity Inc. is poised for growth with a $2 billion peak revenue potential for its flagship drug gedatolisib, a promising development in the biotechnology industry.